They were financed by Advanced Cell Technology, a biotech company with laboratories in Marlborough, Massachusetts, that
recently won approval from the U.S. Food and Drug Administration to test the treatment in 24 patients suffering from either
dry advanced macular degeneration, or a juvenile
form of the disease known as Stargardt's.